Is oral mucositis an inevitable consequence of intensive therapy for hematologic cancers?
Sonis
Stephen T
ST
Brigham and Women's Hospital, Boston, MA 02115, USA. ssonis@partners.org
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D005047:Etoposide / Q000008:administration & dosage; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007262:Infusions, Intravenous; D009061:Mouth Mucosa / Q000473:pathology; D011832:Radiation Injuries / Q000517:prevention & control; D012720:Severity of Illness Index; D013280:Stomatitis / Q000139:chemically induced* / Q000517:prevention & control; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
C496453:FGF7 protein, human; D051523:Fibroblast Growth Factor 7; D005346:Fibroblast Growth Factors; D005047:Etoposide; D003520:Cyclophosphamide